Frequently Asked Questions
The Radiopharmaceutical Theranostics Market was valued at USD 1.6 billion in 2022.
The Radiopharmaceutical Theranostics Market is expected to grow at a CAGR of 11.90% between 2023 and 2030, reaching USD 3.52 billion in 2030.
Cyclotron is the leading segment in source types, holding a significant share in terms of value.
North America region is fuelling the growth of The Radiopharmaceutical Theranostics Market , with a significant share in 2022.
The top players include Bayer AG, GE HealthCare Technologies Inc, Curium, Lantheus Medical Imaging, Inc., Telix Pharmaceuticals Ltd., Cardinal Health Inc, Advanced Accelerator Applications S.A., Jubilant Radiopharma, Theragnostics, NuView Life Sciences
Generating major oncology deals globally and the rise in incidence and prevalence of target conditions are the major drivers of market growth.
Short half-life of radiopharmaceuticals and high equipment prices is the major market restraints.
The rise in initiatives to reduce the demand-supply gap offers a significant growth opportunity for Radiopharmaceutical Theranostics Market.
Targeted therapeutics are leading the market in terms of approach.
Oncology is leading the market growth in terms of application.